Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789416 | 1.00 | LMNA (0.97) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| Hydrochloric Acid SCHEMBL5606289 | 0.98 | LMNA (1.00) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL7657250 | 0.98 | LMNA (0.94) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL1427926 | 0.91 | LMNA (0.81) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL15063358 | 0.86 | ALDH1A1 (0.73) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL6663882 | 0.86 | KMT2A (0.73) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL10862008 | 0.85 | KMT2A (0.71) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL20481400 | 0.84 | LMNA (0.71) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL6640308 | 0.84 | LMNA (0.71) | LMNAALDH1A1KMT2AMEN1OPRM1 | |
| SCHEMBL15063303 | 0.84 | ALDH1A1 (0.71) | LMNAALDH1A1KMT2AMEN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2319540-A1 | Sustained release pharmaceutical compounds to prevent abuse of controlled substances | Shire LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316469-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2266590-A2 | Active agent delivery sytems and methods for protecting and administering active agents | Shire LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7622441-B2 | Sustained release pharmaceutical compounds to prevent abuse of controlled substances | SHIRE LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7247730-B2 | Process for the preparation of dexmethylphenidate hydrochloride | ISP INVESTMENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1490090-A4 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PHARMACEUTICALS INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050080012-A1 | Sustained release pharmaceutical compounds to prevent abuse of controlled substances | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1490090-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040180928-A1 | Process for the preparation of dexmethylphenidate hydrochloride | ISP INVESTMENTS INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | LMNA 760/4885ALDH1A1 2535/4885KMT2A 4227/4885 |
| US-20050080012-A1 | Sustained release pharmaceutical compounds to prevent abuse of controlled substances | CES2, CPA3, ACHE | LMNA 3143/4885ALDH1A1 182/4885KMT2A 3353/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | LMNA 760/4885ALDH1A1 2535/4885KMT2A 4227/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | LMNA 760/4885ALDH1A1 2535/4885KMT2A 4227/4885 |
| US-20040180928-A1 | Process for the preparation of dexmethylphenidate hydrochloride | HTR1A, HTR6, COMT | LMNA 2272/4885ALDH1A1 1137/4885KMT2A 1426/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | LMNA 3203/4885ALDH1A1 2406/4885KMT2A 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.